Contact

All Stories

  1. Comparing clinical effect sizes of Souvenaid TM , lecanemab, and donanemab in early Alzheimer’s disease

    Article • Journal of Alzheimer’s Disease, December 2025, SAGE Publications

    Dr Bruno P Imbimbo

  2. Brain connectivity as a new target for Alzheimer’s disease therapy?

    Article • Brain, November 2025, Oxford University Press (OUP)

    Dr Bruno P Imbimbo, Dr Gilles Allali

  3. Modeling Alzheimer’s disease through the integration of exposome, inflammasome, and connectome

    Article • Neural Regeneration Research, September 2025, Wolters Kluwer Health

    Dr Bruno P Imbimbo

  4. Physical activity and reduced risk of Alzheimer's disease: potential role of soluble amyloid‐β42

    Article • The Journal of Physiology, September 2025, Wiley

    Dr Bruno P Imbimbo

  5. Enhancing uptake of antidiabetic drugs to reduce cardiometabolic risk and dementia burden

    Article • Alzheimer s & Dementia, September 2025, Wiley

    Dr Bruno P Imbimbo

  6. Does p-tau217 play a physiological reparative role in neonates and neurodegenerative diseases?

    Article • Brain Communications, August 2025, Oxford University Press (OUP)

    Dr Bruno P Imbimbo

  7. Restoring amyloid-β42 and γ-secretase function in Alzheimer’s disease

    Article • Brain, August 2025, Oxford University Press (OUP)

    Dr Bruno P Imbimbo

  8. Targeting dementia prevention with semaglutide: The case for APOE4 homozygotes

    Article • Alzheimer s & Dementia, June 2025, Wiley

    Dr Bruno P Imbimbo

  9. Beyond diabetes: Testing long‐term metformin adherence for dementia prevention

    Article • Diabetes Obesity and Metabolism, May 2025, Wiley

    Dr Bruno P Imbimbo

  10. Secretase inhibition in Alzheimer’s therapeutics reveals functional roles of amyloid-beta42

    Article • Neural Regeneration Research, April 2025, Wolters Kluwer Health

    Dr Bruno P Imbimbo

  11. Making a diagnosis of Alzheimer’s disease in asymptomatic individuals with positive biomarkers

    Article • Brain, April 2025, Oxford University Press (OUP)

    Dr Bruno P Imbimbo

  12. CSF amyloid-β40 levels are not associated with efficacy outcomes in Alzheimer’s disease trials

    Article • Brain, April 2025, Oxford University Press (OUP)

    Dr Bruno P Imbimbo

  13. Association between amyloid-β42 levels and neuropsychiatric symptoms in Alzheimer’s disease trials

    Article • Brain Communications, January 2025, Oxford University Press (OUP)

    Dr Bruno P Imbimbo

  14. Can brain network connectivity facilitate the clinical development of disease-modifying anti-Alzheimer drugs?

    Article • Brain Communications, December 2024, Oxford University Press (OUP)

    Dr Bruno P Imbimbo, Dr Gilles Allali

  15. Microglia-mediated neuroimmune suppression in posttraumatic stress disorder

    Article • Proceedings of the National Academy of Sciences, November 2024, Proceedings of the National Academy of Sciences

    Dr Bruno P Imbimbo

  16. Metformin may reduce Alzheimer’s disease risk by increasing soluble amyloid-β42 levels

    Article • Brain, November 2024, Oxford University Press (OUP)

    Dr Bruno P Imbimbo

  17. Increases in amyloid-β42 slow cognitive and clinical decline in Alzheimer’s disease trials

    Article • Brain, September 2024, Oxford University Press (OUP)

    Dr Bruno P Imbimbo

  18. Are we close to using Alzheimer blood biomarkers in clinical practice?

    Article • Neural Regeneration Research, March 2024, Wolters Kluwer Health

    Dr Bruno P Imbimbo

  19. Transferrin-Conjugated Melittin-Loaded L-Arginine-Coated Iron Oxide Nanoparticles for Mitigating Beta-Amyloid Pathology of the 5XFAD Mouse Brain

    Article • International Journal of Molecular Sciences, October 2023, MDPI AG

    Dr Bruno P Imbimbo

  20. Plasma ATN(I) classification and precision pharmacology in Alzheimer's disease

    Article • Alzheimer s & Dementia, April 2023, Wiley

    Dr Bruno P Imbimbo

  21. Initial failures of anti-tau antibodies in Alzheimer’s disease are reminiscent of the amyloid-β story

    Article • Neural Regeneration Research, January 2023, Medknow

    Dr Bruno P Imbimbo

  22. Different Sides of Depression in the Elderly: An In-depth View on the Role of Aβ Peptides

    Article • Current Medicinal Chemistry, November 2022, Bentham Science Publishers

    Dr Bruno P Imbimbo

  23. Should we lower or raise levels of amyloid-β in the brains of Alzheimer patients?

    Article • Pharmacological Research, September 2022, Elsevier

    Dr Bruno P Imbimbo

  24. Does the imbalance in the apolipoprotein E isoforms underlie the pathophysiological process of sporadic Alzheimer's disease?

    Article • Alzheimer s & Dementia, July 2022, Wiley

    Dr Madia Lozupone, Dr Bruno P Imbimbo

  25. Plasma Amyloid-β dynamics in late-life major depression: a longitudinal study

    Article • Translational Psychiatry, July 2022, Springer Science + Business Media

    Dr Bruno P Imbimbo

  26. Editorial: Neurotrophins Biodelivery to CNS: Innovative Approaches for Disease-Modifying Therapy

    Article • Frontiers in Neuroscience, May 2022, Frontiers

    Dr Bruno P Imbimbo

  27. Molecular mechanisms of skin wound healing in non-diabetic and diabetic mice in excision and pressure experimental wounds

    Article • Cell and Tissue Research, April 2022, Springer Science + Business Media

    Dr Bruno P Imbimbo

  28. Are apolipoprotein E fragments a promising new therapeutic target for Alzheimer’s disease?

    Article • Therapeutic Advances in Chronic Disease, January 2022, SAGE Publications

    Dr Bruno P Imbimbo, Dr Madia Lozupone

  29. What have we learned from past failures of investigational drugs for Alzheimer’s disease?

    Article • Expert Opinion on Investigational Drugs, December 2021, Taylor & Francis

    Dr Bruno P Imbimbo

  30. Can platelet activation result in increased plasma Aβ levels and contribute to the pathogenesis of Alzheimer’s disease?

    Article • Ageing Research Reviews, November 2021, Elsevier

    Dr Bruno P Imbimbo

  31. A critical appraisal of tau‐targeting therapies for primary and secondary tauopathies

    Article • Alzheimer s & Dementia, September 2021, Wiley

    Dr Bruno P Imbimbo

  32. Evidence of upregulation of the cholinergic anti-inflammatory pathway in late-life depression

    Article • Journal of Affective Disorders, May 2021, Elsevier

    Dr Bruno P Imbimbo

  33. Brain Amyloid Deposition in Late-Life Depression

    Article • Biological Psychiatry, April 2021, Elsevier

    Dr Bruno P Imbimbo

  34. The β-Secretase BACE1 in Alzheimer’s Disease

    Article • Biological Psychiatry, April 2021, Elsevier

    Dr Bruno P Imbimbo

  35. Accelerating Alzheimer’s disease drug discovery and development: what’s the way forward?

    Article • Expert Opinion on Drug Discovery, March 2021, Taylor & Francis

    Dr Bruno P Imbimbo

  36. Can Anti–β-amyloid Monoclonal Antibodies Work in Autosomal Dominant Alzheimer Disease?

    Article • Neurology Genetics, February 2021, Wolters Kluwer Health

    Dr Bruno P Imbimbo

  37. MiRNA-15b and miRNA-125b are associated with regional Aβ-PET and FDG-PET uptake in cognitively normal individuals with subjective memory complaints

    Article • Translational Psychiatry, January 2021, Springer Science + Business Media

    Dr Bruno P Imbimbo

  38. Association of plasma YKL-40 with brain amyloid-β levels, memory performance, and sex in subjective memory complainers

    Article • Neurobiology of Aging, December 2020, Elsevier

    Dr Bruno P Imbimbo

  39. Age and sex impact plasma NFL and t-Tau trajectories in individuals with subjective memory complaints: a 3-year follow-up study

    Article • Alzheimer s Research & Therapy, November 2020, Springer Science + Business Media

    Dr Bruno P Imbimbo

  40. Effects of Topical Application of CHF6467, a Mutated Form of Human Nerve Growth Factor, on Skin Wound Healing in Diabetic Mice

    Article • Journal of Pharmacology and Experimental Therapeutics, November 2020, Elsevier

    Dr Bruno P Imbimbo

  41. Impairment of the cholinergic anti-inflammatory pathway in older subjects with severe COVID-19

    Article • Medical Hypotheses, November 2020, Elsevier

    Dr Bruno P Imbimbo

  42. Pharmacological management of dementia with Lewy bodies with a focus on zonisamide for treating parkinsonism

    Article • Expert Opinion on Pharmacotherapy, October 2020, Taylor & Francis

    Dr Madia Lozupone, Dr Bruno P Imbimbo

  43. Discontinued disease-modifying therapies for Alzheimer’s disease: status and future perspectives

    Article • Expert Opinion on Investigational Drugs, July 2020, Taylor & Francis

    Dr Bruno P Imbimbo, Dr Madia Lozupone

  44. Should drug discovery scientists still embrace the amyloid hypothesis for Alzheimer’s disease or should they be looking elsewhere?

    Article • Expert Opinion on Drug Discovery, July 2020, Taylor & Francis

    Dr Bruno P Imbimbo

  45. A Path Toward Precision Medicine for Neuroinflammatory Mechanisms in Alzheimer's Disease

    Article • Frontiers in Immunology, March 2020, Frontiers

    Dr Bruno P Imbimbo

  46. Development of disease-modifying drugs for frontotemporal dementia spectrum disorders

    Article • Nature Reviews Neurology, March 2020, Springer Science + Business Media

    Dr Bruno P Imbimbo, Francesco Panza, Dr Madia Lozupone

  47. Liver fibrosis score, physical frailty, and the risk of dementia in older adults: The Italian Longitudinal Study on Aging

    Article • Alzheimer s & Dementia Translational Research & Clinical Interventions, January 2020, Wiley

    Dr Bruno P Imbimbo, Dr Madia Lozupone

  48. Perspective: Is therapeutic plasma exchange a viable option for treating Alzheimer's disease?

    Article • Alzheimer s & Dementia Translational Research & Clinical Interventions, January 2020, Wiley

    Dr Bruno P Imbimbo

  49. Do anti-amyloid-β drugs affect neuropsychiatric status in Alzheimer’s disease patients?

    Article • Ageing Research Reviews, November 2019, Elsevier

    Dr Madia Lozupone, Dr Bruno P Imbimbo

  50. Structure-activity relationships of flurbiprofen analogues as stabilizers of the amyloidogenic protein transthyretin

    Article • Journal of Structural Biology, November 2019, Elsevier

    Dr Bruno P Imbimbo

  51. Investigational BACE inhibitors for the treatment of Alzheimer’s disease

    Article • Expert Opinion on Investigational Drugs, October 2019, Taylor & Francis

    Dr Bruno P Imbimbo

  52. Time to test antibacterial therapy in Alzheimer’s disease

    Article • Brain, August 2019, Oxford University Press (OUP)

    Dr Madia Lozupone, Dr Bruno P Imbimbo, Francesco Panza

  53. Drug-induced reductions in brain amyloid-β levels may adversely affect cognition and behavior by a disruption of functional connectivity homeostasis

    Article • Neurodegenerative Disease Management, August 2019, Future Medicine

    Dr Bruno P Imbimbo

  54. Do BACE inhibitor failures in Alzheimer patients challenge the amyloid hypothesis of the disease?

    Article • Expert Review of Neurotherapeutics, May 2019, Taylor & Francis

    Dr Madia Lozupone, Dr Bruno P Imbimbo, Francesco Panza

  55. Disease-modifying therapies for tauopathies: agents in the pipeline

    Article • Expert Review of Neurotherapeutics, April 2019, Taylor & Francis

    Professor Francesco Panza, Dr Madia Lozupone, Professor GIANCARLO G LOGROSCINO, Dr Bruno P Imbimbo, Francesco Panza

  56. Promising therapies for the treatment of frontotemporal dementia clinical phenotypes: from symptomatic to disease-modifying drugs

    Article • Expert Opinion on Pharmacotherapy, April 2019, Taylor & Francis

    Professor GIANCARLO G LOGROSCINO, Dr Madia Lozupone, Vittorio Dibello, Dr Bruno P Imbimbo, Dr Vittorio Dibello

  57. Amyloid-β immunotherapy for alzheimer disease: Is it now a long shot?

    Article • Annals of Neurology, January 2019, Wiley

    Dr Madia Lozupone, Dr Bruno P Imbimbo, Francesco Panza

  58. A critical appraisal of amyloid-β-targeting therapies for Alzheimer disease

    Article • Nature Reviews Neurology, January 2019, Springer Science + Business Media

    Dr Madia Lozupone, Dr Bruno P Imbimbo, Francesco Panza

  59. Are antibodies directed against amyloid-β (Aβ) oligomers the last call for the Aβ hypothesis of Alzheimer's disease?

    Article • Immunotherapy, January 2019, Future Medicine

    Dr Madia Lozupone, Dr Bruno P Imbimbo, Dr Vittorio Dibello

  60. BACE inhibitors in clinical development for the treatment of Alzheimer’s disease

    Article • Expert Review of Neurotherapeutics, October 2018, Taylor & Francis

    Dr Madia Lozupone, Vittorio Dibello, Professor GIANCARLO G LOGROSCINO, Dr Vittorio Dibello, Dr Bruno P Imbimbo, Francesco Panza

  61. Social Dysfunction in Older Age and Relationships with Cognition, Depression, and Apathy: The GreatAGE Study

    Article • Journal of Alzheimer’s Disease, September 2018, IOS Press

    Francesco Panza, Dr Madia Lozupone, Dr Bruno P Imbimbo

  62. Amyloid deposition in a mouse model humanized at the transthyretin and retinol-binding protein 4 loci

    Article • Laboratory Investigation, January 2018, Springer Science + Business Media

    Dr Bruno P Imbimbo

  63. The potential of solanezumab and gantenerumab to prevent Alzheimer’s disease in people with inherited mutations that cause its early onset

    Article • Expert Opinion on Biological Therapy, October 2017, Taylor & Francis

    Dr Madia Lozupone, Dr Bruno P Imbimbo, Francesco Panza, Dr Vittorio Dibello

  64. Relationships of Dietary Patterns, Foods, and Micro- and Macronutrients with Alzheimer’s Disease and Late-Life Cognitive Disorders: A Systematic Review

    Article • Journal of Alzheimer’s Disease, July 2017, IOS Press

    Francesco Panza, Dr Madia Lozupone, Dr Bruno P Imbimbo

  65. Midlife Metabolic Profile and the Risk of Late-Life Cognitive Decline

    Article • Journal of Alzheimer’s Disease, July 2017, IOS Press

    Professor GIANCARLO G LOGROSCINO, Francesco Panza, Dr Madia Lozupone, Dr Bruno P Imbimbo

  66. Neuroprotective and Anti-Apoptotic Effects of CSP-1103 in Primary Cortical Neurons Exposed to Oxygen and Glucose Deprivation

    Article • International Journal of Molecular Sciences, January 2017, MDPI AG

    Dr Bruno P Imbimbo

  67. CSP-1103 (CHF5074) stabilizes human transthyretin in healthy human subjects

    Article • Amyloid, January 2017, Taylor & Francis

    Dr Bruno P Imbimbo

  68. Reversible Cognitive Frailty, Dementia, and All-Cause Mortality. The Italian Longitudinal Study on Aging

    Article • Journal of the American Medical Directors Association, January 2017, Elsevier

    Francesco Panza, Dr Madia Lozupone, Dr Bruno P Imbimbo

  69. Bipolar Disorder and Frontotemporal Dementia: An Intriguing Association

    Article • Journal of Alzheimer’s Disease, December 2016, IOS Press

    Francesco Panza, Dr Madia Lozupone, Dr Bruno P Imbimbo

  70. Emerging drugs to reduce abnormal β-amyloid protein in Alzheimer’s disease patients

    Article • Expert Opinion on Emerging Drugs, October 2016, Taylor & Francis

    Dr Madia Lozupone, Dr Bruno P Imbimbo, Francesco Panza

  71. Tau-based therapeutics for Alzheimer’s disease: active and passive immunotherapy

    Article • Immunotherapy, September 2016, Future Medicine

    Professor Francesco Panza, Francesco Panza, Dr Madia Lozupone, Dr Bruno P Imbimbo

  72. Tau-directed approaches for the treatment of Alzheimer’s disease: focus on leuco-methylthioninium

    Article • Expert Review of Neurotherapeutics, February 2016, Informa Healthcare

    Francesco Panza, Dr Madia Lozupone, Dr Bruno P Imbimbo

  73. Tau aggregation inhibitors: the future of Alzheimer’s pharmacotherapy?

    Article • Expert Opinion on Pharmacotherapy, February 2016, Informa Healthcare

    Francesco Panza, Dr Madia Lozupone, Dr Bruno P Imbimbo

  74. Examination of level of knowledge in Italian general practitioners attending an education session on diagnosis and management of the early stage of Alzheimer's disease: pass or fail?

    Article • International Psychogeriatrics, January 2016, Cambridge University Press

    Dr Madia Lozupone, Dr Bruno P Imbimbo, Francesco Panza

  75. Tau-Centric Targets and Drugs in Clinical Development for the Treatment of Alzheimer’s Disease

    Article • BioMed Research International, January 2016, Hindawi Publishing Corporation

    Francesco Panza, Dr Madia Lozupone, Dr Bruno P Imbimbo

  76. Progresses in treating agitation: a major clinical challenge in Alzheimer’s disease

    Article • Expert Opinion on Pharmacotherapy, September 2015, Informa Healthcare

    Francesco Panza, Dr Madia Lozupone, Dr Bruno P Imbimbo

  77. Coffee Consumption Habits and the Risk of Mild Cognitive Impairment: The Italian Longitudinal Study on Aging

    Article • Journal of Alzheimer’s Disease, August 2015, IOS Press

    Dr Bruno P Imbimbo, Francesco Panza

  78. CHF5074 (CSP-1103) induces microglia alternative activation in plaque-free Tg2576 mice and primary glial cultures exposed to beta-amyloid

    Article • Neuroscience, August 2015, Elsevier

    Dr Bruno P Imbimbo

  79. Age-related hearing impairment and frailty in Alzheimer's disease: interconnected associations and mechanisms

    Article • Frontiers in Aging Neuroscience, June 2015, Frontiers

    Francesco Panza, Dr Bruno P Imbimbo

  80. CHF5074 (CSP-1103) stabilizes human transthyretin in mice humanized at the transthyretin and retinol-binding protein loci

    Article • FEBS Letters, February 2015, Wiley

    Dr Bruno P Imbimbo

  81. Efficacy and safety studies of gantenerumab in patients with Alzheimer’s disease

    Article • Expert Review of Neurotherapeutics, August 2014, Informa Healthcare

    Francesco Panza, Dr Bruno P Imbimbo

  82. Amyloid-directed monoclonal antibodies for the treatment of Alzheimer’s disease: the point of no return?

    Article • Expert Opinion on Biological Therapy, June 2014, Informa Healthcare

    Francesco Panza, Dr Bruno P Imbimbo

  83. Pharmacological targeting of the β-amyloid precursor protein intracellular domain

    Article • Scientific Reports, April 2014, Nature

    prof, MD Laura Calza, Dr Bruno P Imbimbo

  84. CHF5074 and LY450139 sub-acute treatments differently affect cortical extracellular glutamate levels in pre-plaque Tg2576 mice

    Article • Neuroscience, April 2014, Elsevier

    Dr Bruno P Imbimbo

  85. Is there still any hope for amyloid-based immunotherapy for Alzheimerʼs disease?

    Article • Current Opinion in Psychiatry, March 2014, Wolters Kluwer Health

    Francesco Panza, Dr Bruno P Imbimbo

  86. Electrophysiological and metabolic effects of CHF5074 in the hippocampus: Protection against in vitro ischemia

    Article • Pharmacological Research, March 2014, Elsevier

    Dr Bruno P Imbimbo

  87. Amyloid-based immunotherapy for Alzheimer's disease in the time of prevention trials: the way forward

    Article • Expert Review of Clinical Immunology, February 2014, Informa Healthcare

    Francesco Panza, Dr Bruno P Imbimbo

  88. CHF5074 Reduces Biomarkers of Neuroinflammation in Patients with Mild Cognitive Impairment: A 12-Week, Double-Blind, Placebo- Controlled Study

    Article • Current Alzheimer Research, August 2013, Bentham Science Publishers

    prof, MD Laura Calza, Dr Bruno P Imbimbo

  89. Structural evidence for native state stabilization of a conformationally labile amyloidogenic transthyretin variant by fibrillogenesis inhibitors

    Article • FEBS Letters, June 2013, Wiley

    Dr Bruno P Imbimbo

  90. Receptor for Advanced Glycation End Products Contributes to Postnatal Pulmonary Development and Adult Lung Maintenance Program in Mice

    Article • American Journal of Respiratory Cell and Molecular Biology, February 2013, American Thoracic Society

    Dr Bruno P Imbimbo

  91. CHF5074 restores visual memory ability and pre-synaptic cortical acetylcholine release in pre-plaque Tg2576 mice

    Article • Journal of Neurochemistry, January 2013, Wiley

    prof, MD Laura Calza, Dr Bruno P Imbimbo

  92. Pharmacokinetics and Pharmacodynamics of CHF5074 After Short-term Administration in Healthy Subjects

    Article • Alzheimer Disease & Associated Disorders, January 2013, Wolters Kluwer Health

    prof, MD Laura Calza, Dr Bruno P Imbimbo

  93. Multi-target action of the novel anti-Alzheimer compound CHF5074: in vivo study of long term treatment in Tg2576 mice

    Article • BMC Neuroscience, January 2013, Springer Science + Business Media

    prof, MD Laura Calza, Dr Bruno P Imbimbo

  94. γ-Secretase Pharmacology: What Pharmacology Will Work for Alzheimer's Disease?

    Article • International Journal of Alzheimer s Disease, January 2013, Hindawi Publishing Corporation

    Dr Bruno P Imbimbo

  95. Frailty syndrome and the risk of vascular dementia: The Italian Longitudinal Study on Aging

    Article • Alzheimer s & Dementia, December 2012, Wiley

    Dr Bruno P Imbimbo, Francesco Panza

  96. Amyloid-related imaging abnormalities associated with immunotherapy in Alzheimer’s disease patients

    Article • Future Neurology, July 2012, Future Medicine

    Francesco Panza, Dr Bruno P Imbimbo

  97. Metabolic-Cognitive Syndrome: Metabolic Approach for the Management of Alzheimer's Disease Risk

    Article • Journal of Alzheimer’s Disease, June 2012, IOS Press

    Dr Bruno P Imbimbo

  98. Alcohol consumption in mild cognitive impairment and dementia: harmful or neuroprotective?

    Article • International Journal of Geriatric Psychiatry, March 2012, Wiley

    Francesco Panza, Dr Bruno P Imbimbo

  99. Immunotherapy for Alzheimer’s disease: from anti-β-amyloid to tau-based immunization strategies

    Article • Immunotherapy, February 2012, Future Medicine

    Francesco Panza, Dr Bruno P Imbimbo

  100. Solanezumab for the treatment of mild-to-moderate Alzheimer’s disease

    Article • Expert Review of Clinical Immunology, February 2012, Informa Healthcare

    Francesco Panza, Dr Bruno P Imbimbo

  101. Therapeutic effect of CHF5074, a new γ-secretase modulator, in a mouse model of scrapie

    Article • Prion, January 2012, Taylor & Francis

    Dr Bruno P Imbimbo

  102. Angiotensin-converting enzyme inhibitors and incidence of mild cognitive impairment. The Italian Longitudinal Study on Aging

    Article • AGE, December 2011, Springer Science + Business Media

    Dr Bruno P Imbimbo, Francesco Panza

  103. Advances in the identification of γ-secretase inhibitors for the treatment of Alzheimer's disease

    Article • Expert Opinion on Drug Discovery, December 2011, Informa Healthcare

    Francesco Panza, Dr Bruno P Imbimbo

  104. Interacting with γSecretase for Treating Alzheimer's Disease: From Inhibition to Modulation

    Article • Current Medicinal Chemistry, December 2011, Bentham Science Publishers

    Dr Bruno P Imbimbo, Francesco Panza

  105. Anti-β-Amyloid Immunotherapy for Alzheimers Disease: Focus on Bapineuzumab

    Article • Current Alzheimer Research, December 2011, Bentham Science Publishers

    Francesco Panza, Dr Bruno P Imbimbo

  106. Metabolic Syndrome, Mild Cognitive Impairment and Dementia

    Article • Current Alzheimer Research, August 2011, Bentham Science Publishers

    Dr Bruno P Imbimbo, Francesco Panza

  107. Mediterranean Diet in Predementia and Dementia Syndromes

    Article • Current Alzheimer Research, August 2011, Bentham Science Publishers

    Dr Bruno P Imbimbo, Francesco Panza

  108. γ-Secretase Inhibitors and Modulators for the Treatment of Alzheimer's Disease: Disappointments and Hopes

    Article • Current Topics in Medicinal Chemistry, June 2011, Bentham Science Publishers

    Dr Bruno P Imbimbo

  109. The γ-Secretase Modulator CHF5074 Restores Memory and Hippocampal Synaptic Plasticity in Plaque-Free Tg2576 Mice

    Article • Journal of Alzheimer’s Disease, May 2011, IOS Press

    Dr Bruno P Imbimbo

  110. Monoclonal antibodies against β-amyloid (Aβ) for the treatment of Alzheimer's disease: the Aβ target at a crossroads

    Article • Expert Opinion on Biological Therapy, May 2011, Informa Healthcare

    Francesco Panza, Dr Bruno P Imbimbo

  111. Diet and Alzheimer’s disease risk factors or prevention: the current evidence

    Article • Expert Review of Neurotherapeutics, May 2011, Informa Healthcare

    Francesco Panza, Dr Bruno P Imbimbo

  112. Therapeutic intervention for Alzheimer's disease with γ-secretase inhibitors: still a viable option?

    Article • Expert Opinion on Investigational Drugs, January 2011, Informa Healthcare

    Francesco Panza, Dr Bruno P Imbimbo

  113. Gerontechnology for Demented Patients: Smart Homes for Smart Aging

    Article • Journal of Alzheimer’s Disease, January 2011, IOS Press

    Dr Bruno P Imbimbo

  114. Aluminium in the Diet, Cognitive Decline and Dementia

    Article • January 2011, Springer Science + Business Media

    Francesco Panza, Dr Bruno P Imbimbo

  115. The γ-Secretase Modulator CHF5074 Reduces the Accumulation of Native Hyperphosphorylated Tau in a Transgenic Mouse Model of Alzheimer’s Disease

    Article • Journal of Molecular Neuroscience, December 2010, Springer Science + Business Media

    Dr Bruno P Imbimbo

  116. Polymorphisms in GlutathioneS-Transferase Omega-1 Gene and Increased Risk of Sporadic Alzheimer Disease

    Article • Rejuvenation Research, December 2010, Mary Ann Liebert Inc

    Francesco Panza, Dr Bruno P Imbimbo

  117. Nutraceutical Properties of Mediterranean Diet and Cognitive Decline: Possible Underlying Mechanisms

    Article • Journal of Alzheimer’s Disease, November 2010, IOS Press

    Francesco Panza, Dr Bruno P Imbimbo

  118. Bapineuzumab: anti-β-amyloid monoclonal antibodies for the treatment of Alzheimer’s disease

    Article • Immunotherapy, November 2010, Future Medicine

    Francesco Panza, Dr Bruno P Imbimbo

  119. Are γ-secretase inhibitors detrimental for Alzheimer's disease patients?

    Article • Journal of Alzheimer’s Disease, October 2010, IOS Press

    Dr Bruno P Imbimbo

  120. Peripheral Antioxidant Markers in Mild Cognitive Impairment and its Progression to Dementia

    Article • Journal of Alzheimer’s Disease, September 2010, IOS Press

    Francesco Panza, Dr Bruno P Imbimbo

  121. Metabolic Syndrome and Cognitive Impairment: Current Epidemiology and Possible Underlying Mechanisms

    Article • Journal of Alzheimer’s Disease, September 2010, IOS Press

    Francesco Panza, Dr Bruno P Imbimbo

  122. Dietary Unsaturated Fatty Acids and Risk of Mild Cognitive Impairment

    Article • Journal of Alzheimer’s Disease, September 2010, IOS Press

    Dr Bruno P Imbimbo, Francesco Panza

  123. Is Insulin Resistant Brain State a Central Feature of the Metabolic-Cognitive Syndrome?

    Article • Journal of Alzheimer’s Disease, July 2010, IOS Press

    Francesco Panza, Dr Bruno P Imbimbo

  124. Comparison of Pharmacological Modulation of APP Metabolism in Primary Chicken Telencephalic Neurons and in a Human Neuroglioma Cell Line

    Article • Journal of Molecular Neuroscience, July 2010, Springer Science + Business Media

    Dr Bruno P Imbimbo

  125. REVIEW: γ‐Secretase Inhibitors for the Treatment of Alzheimer's Disease: The Current State

    Article • CNS Neuroscience & Therapeutics, June 2010, Wiley

    Francesco Panza, Dr Bruno P Imbimbo

  126. Aluminum in the Diet and Alzheimer's Disease: From Current Epidemiology to Possible Disease-Modifying Treatment

    Article • Journal of Alzheimer’s Disease, March 2010, IOS Press

    Francesco Panza, Dr Bruno P Imbimbo

  127. CHF5074, a Novel γ-Secretase Modulator, Restores Hippocampal Neurogenesis Potential and Reverses Contextual Memory Deficit in a Transgenic Mouse Model of Alzheimer's Disease

    Article • Journal of Alzheimer’s Disease, March 2010, IOS Press

    Dr Bruno P Imbimbo

  128. Interleukin 6–174 G/C promoter and variable number of tandem repeats (VNTR) gene polymorphisms in sporadic Alzheimer's disease

    Article • Progress in Neuro-Psychopharmacology and Biological Psychiatry, February 2010, Elsevier

    Dr Bruno P Imbimbo, Francesco Panza

  129. Late-Life Depression, Mild Cognitive Impairment, and Dementia: Possible Continuum?

    Article • American Journal of Geriatric Psychiatry, February 2010, Elsevier

    Francesco Panza, Dr Bruno P Imbimbo

  130. Towards Disease-Modifying Treatment of Alzheimers Disease: Drugs Targeting β -Amyloid

    Article • Current Alzheimer Research, February 2010, Bentham Science Publishers

    Dr Bruno P Imbimbo, Francesco Panza

  131. Are NSAIDs useful to treat Alzheimer’s disease or mild cognitive impairment?

    Article • Frontiers in Aging Neuroscience, January 2010, Frontiers

    Dr Bruno P Imbimbo, Francesco Panza

  132. Beyond the neurotransmitter-focused approach in treating Alzheimer’s Disease: drugs targeting β-amyloid and tau protein

    Article • Aging Clinical and Experimental Research, December 2009, Springer Science + Business Media

    Francesco Panza, Dr Bruno P Imbimbo

  133. Medicinal chemistry and therapeutic potential of muscarinic M3 antagonists

    Article • Medicinal Research Reviews, November 2009, Wiley

    Dr Bruno P Imbimbo

  134. Why Did Tarenflurbil Fail in Alzheimer's Disease?

    Article • Journal of Alzheimer’s Disease, July 2009, IOS Press

    Dr Bruno P Imbimbo

  135. An update on the efficacy of non-steroidal anti-inflammatory drugs in Alzheimer's disease

    Article • Expert Opinion on Investigational Drugs, July 2009, Informa Healthcare

    Dr Bruno P Imbimbo

  136. Disease-Modifying Approach to the Treatment of Alzheimerʼs Disease

    Article • Drugs & Aging, July 2009, Springer Science + Business Media

    Francesco Panza, Dr Bruno P Imbimbo

  137. CHF5074, a novel γ-secretase modulator, attenuates brain β-amyloid pathology and learning deficit in a mouse model of Alzheimer's disease

    Article • British Journal of Pharmacology, March 2009, Wiley

    Dr Bruno P Imbimbo

  138. Polyunsaturated Fatty Acid and S-Adenosylmethionine Supplementation in Predementia Syndromes and Alzheimer's Disease: A Review

    Article • The Scientific World JOURNAL, January 2009, Hindawi Publishing Corporation

    Francesco Panza, Dr Bruno P Imbimbo

  139. Alzheimer's disease: γ-secretase inhibitors

    Article • Drug Discovery Today Therapeutic Strategies, September 2008, Elsevier

    Dr Bruno P Imbimbo

  140. Editorial [Hot Topic:Gamma-Secretase Inhibitors and Modulators as a Therapeutic Approach to Alzheimers disease (Guest Editor: Bruno P. Imbimbo)]

    Article • Current Topics in Medicinal Chemistry, January 2008, Bentham Science Publishers

    Dr Bruno P Imbimbo

  141. Therapeutic Potential of γ -Secretase Inhibitors and Modulators

    Article • Current Topics in Medicinal Chemistry, January 2008, Bentham Science Publishers

    Dr Bruno P Imbimbo

  142. 1-(3′,4′-Dichloro-2-fluoro[1,1′-biphenyl]-4-yl)-cyclopropanecarboxylic Acid (CHF5074), a Novel γ-Secretase Modulator, Reduces Brain β-Amyloid Pathology in a Transgenic Mouse Model of Alzheimer's Disease without Causing Peripheral Toxicity

    Article • Journal of Pharmacology and Experimental Therapeutics, September 2007, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Dr Bruno P Imbimbo

  143. Discovery of Diaryl Imidazolidin-2-one Derivatives, a Novel Class of Muscarinic M3 Selective Antagonists (Part 1)

    Article • Journal of Medicinal Chemistry, April 2007, American Chemical Society (ACS)

    Dr Bruno P Imbimbo

  144. In vitro and in vivo profiling of CHF5022 and CHF5074

    Article • Pharmacological Research, April 2007, Elsevier

    Dr Bruno P Imbimbo

  145. Discovery of Diaryl Imidazolidin-2-one Derivatives, a Novel Class of Muscarinic M3 Selective Antagonists (Part 2)

    Article • Journal of Medicinal Chemistry, March 2007, American Chemical Society (ACS)

    Dr Bruno P Imbimbo

  146. Conformation-sensitive Antibodies against Alzheimer Amyloid-β by Immunization with a Thioredoxin-constrained B-cell Epitope Peptide

    Article • Journal of Biological Chemistry, January 2007, American Society for Biochemistry & Molecular Biology (ASBMB)

    Dr Bruno P Imbimbo

  147. CHF3381, a N-methyl-D-aspartate Receptor Antagonist and Monoamine Oxidase–A Inhibitor, Attenuates Secondary Hyperalgesia in a Human Pain Model

    Article • Journal of Pain, August 2006, Elsevier

    Dr Bruno P Imbimbo

  148. Pathophysiology of Alzheimer's Disease

    Article • Neuroimaging Clinics of North America, November 2005, Elsevier

    Dr Bruno P Imbimbo

  149. β-Amyloid Therapeutic Strategies for Alzheimer's Disease

    Article • October 2005, Wiley

    Dr Bruno P Imbimbo

  150. Synthesis and Biological Activity of Flurbiprofen Analogues as Selective Inhibitors of β-Amyloid1-42Secretion

    Article • Journal of Medicinal Chemistry, September 2005, American Chemical Society (ACS)

    Dr Bruno P Imbimbo

  151. Steady-state pharmacokinetics and pharmacodynamics of CHF3381, a novel antineuropathic pain agent, in healthy subjects

    Article • British Journal of Clinical Pharmacology, April 2005, Wiley

    Dr Bruno P Imbimbo

  152. Mechanistic Pharmacokinetic and Pharmacodynamic Modeling of CHF3381 (2-[(2,3-Dihydro-1H-inden-2-yl)amino]acetamide Monohydrochloride), a Novel N-Methyl-d-aspartate Antagonist and Monoamine Oxidase-A Inhibitor in Healthy Subjects

    Article • Journal of Pharmacology and Experimental Therapeutics, January 2005, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Dr Bruno P Imbimbo

  153. High Throughput Screening of β-Amyloid Secretion Inhibitors Using Homogenous Time-Resolved Fluorescence

    Article • Combinatorial Chemistry & High Throughput Screening, December 2004, Bentham Science Publishers

    Dr Bruno P Imbimbo

  154. The potential role of non-steroidal anti-inflammatory drugs in treating Alzheimer’s disease

    Article • Expert Opinion on Investigational Drugs, November 2004, Informa Healthcare

    Dr Bruno P Imbimbo

  155. P4-342 High throughput screening of β-amyloid secretion inhibitors using homogenous time-resolved fluorescence

    Article • Neurobiology of Aging, July 2004, Elsevier

    Dr Bruno P Imbimbo

  156. O3-06-05 New flurbiprofen analogues, devoid of cyclooxygenase activity, selectively lower β-amyloid1–42 secretion

    Article • Neurobiology of Aging, July 2004, Elsevier

    Dr Bruno P Imbimbo

  157. Ganstigmine and donepezil improve neurodegeneration in AD11 antinerve growth factor transgenic mice

    Article • American Journal of Alzheimer s Disease & Other Dementias®, May 2004, SAGE Publications

    Dr Bruno P Imbimbo

  158. Safety, Pharmacokinetics, and Pharmacodynamics of CHF 3381, a Novel N-Methyl-D-Aspartate Antagonist, after Single Oral Doses in Healthy Subjects

    Article • The Journal of Clinical Pharmacology, August 2003, Wiley

    Dr Bruno P Imbimbo

  159. The protective effect of ganstigmine against amyloid beta25–35 neurotoxicity on chicken cortical neurons is independent from the cholinesterase inhibition

    Article • Neuroscience Letters, May 2003, Elsevier

    Dr Bruno P Imbimbo

  160. Perspectives on the Pharmacological Treatment of Dementia

    Article • March 2003, Taylor & Francis

    Dr Bruno P Imbimbo

  161. ?-Amyloid immunization approaches for Alzheimer's disease

    Article • Drug Development Research, June 2002, Wiley

    Dr Bruno P Imbimbo

  162. Toxicity of ?-amyloid vaccination in patients with Alzheimer's disease

    Article • Annals of Neurology, May 2002, Wiley

    Dr Bruno P Imbimbo

  163. Pharmacodynamic-Tolerability Relationships of Cholinesterase Inhibitors for Alzheimer??s Disease

    Article • CNS Drugs, January 2001, Springer Science + Business Media

    Dr Bruno P Imbimbo

  164. Central acetylcholinesterase inhibition in Alzheimer patients

    Article • Annals of Neurology, January 2001, Wiley

    Dr Bruno P Imbimbo

  165. Hemodynamic effects of MF 10058, a new cardioselective muscarinic M2 receptor antagonist, in conscious dogs

    Article • European Journal of Pharmacology, October 2000, Elsevier

    Dr Bruno P Imbimbo

  166. A 6-Month, Double-Blind, Placebo-Controlled Trial of Eptastigmine in Alzheimer’s Disease

    Article • Dementia and Geriatric Cognitive Disorders, January 2000, Karger Publishers

    Dr Bruno P Imbimbo

  167. Synthesis of New Cardioselective M2 Muscarinic Receptor Antagonists.

    Article • Chemical and Pharmaceutical Bulletin, January 2000, Pharmaceutical Society of Japan

    Dr Bruno P Imbimbo

  168. PHARMACODYNAMICS OF A LONG ACTING DEPOT PREPARATION OF AVORELIN IN PATIENTS WITH PROSTATE CANCER

    Article • The Journal of Urology, December 1999, Wolters Kluwer Health

    Dr Bruno P Imbimbo

  169. Suicide in Two Patients with a Diagnosis of Probable Alzheimer Disease

    Article • Alzheimer Disease & Associated Disorders, April 1999, Wolters Kluwer Health

    Dr Bruno P Imbimbo

  170. Efficacy and safety of eptastigmine for the treatment of patients with Alzheimer's disease

    Article • Neurology, March 1999, Wolters Kluwer Health

    Dr Bruno P Imbimbo

  171. Two-Year Treatment of Alzheimer’s Disease with Eptastigmine

    Article • Dementia and Geriatric Cognitive Disorders, January 1999, Karger Publishers

    Dr Bruno P Imbimbo

  172. Acetylcholinesterase assay may predict cognitive response of Alzheimer patients to eptastigmine treatment

    Article • European Journal of Clinical Pharmacology, December 1998, Springer Science + Business Media

    Dr Bruno P Imbimbo

  173. A 25-Week Placebo-Controlled Study of Eptastigmine in Patients with Alzheimer Disease

    Article • Alzheimer Disease & Associated Disorders, December 1998, Wolters Kluwer Health

    Dr Bruno P Imbimbo

  174. Cardiac Autonomic Dysfunction in Patients with Alzheimer Disease: Possible Pathogenetic Mechanisms

    Article • Alzheimer Disease & Associated Disorders, December 1998, Wolters Kluwer Health

    Dr Bruno P Imbimbo

  175. Maximum Tolerated Dose and Pharmacodynamics of Eptastigmine in Elderly Healthy Volunteers

    Article • The Journal of Clinical Pharmacology, July 1998, Wiley

    Dr Bruno P Imbimbo

  176. Effect of food on the absorption of eptastigmine

    Article • European Journal of Clinical Pharmacology, June 1998, Springer Science + Business Media

    Dr Bruno P Imbimbo

  177. Lack of effect of hexarelin on TRH-induced TSH response in normal adult man

    Article • Journal of Endocrinological Investigation, April 1998, Springer Science + Business Media

    Dr Bruno P Imbimbo

  178. The long-term efficacy and safety of two different corticosteroids in chronic sarcoidosis

    Article • Respiratory Medicine, September 1997, Elsevier

    Dr Bruno P Imbimbo

  179. Acute administration of hexarelin stimulates GH secretion during day and night in normal men

    Article • Clinical Endocrinology, March 1997, Wiley

    Dr Bruno P Imbimbo

  180. Population pharmacokinetics of rufloxacin in patients with acute exacerbations of chronic bronchitis

    Article • European Journal of Pharmaceutical Sciences, January 1997, Elsevier

    Dr Bruno P Imbimbo

  181. Eptastigmine: A Cholinergic Approach to the Treatment of Alzheimer’s Disease

    Article • January 1997, Springer Science + Business Media

    Dr Bruno P Imbimbo

  182. Relationship between pharmacodynamic activity and cognitive effects of eptastigmine in patients with Alzheimer's disease*

    Article • Clinical Pharmacology & Therapeutics, August 1996, Springer Science + Business Media

    Dr Bruno P Imbimbo

  183. Pharmacodynamic monitoring of eptastigmine in capillary blood

    Article • European Journal of Clinical Pharmacology, July 1996, Springer Science + Business Media

    Dr Bruno P Imbimbo

  184. Effects of Hexarelin on Growth Hormone Secretion in Short Normal Children, in Obese Children, and in Subjects with Growth Hormone Deficiency

    Article • January 1996, Springer Science + Business Media

    Dr Bruno P Imbimbo

  185. The effect of hexarelin on growth hormone (GH) secretion in patients with GH deficiency.

    Article • The Journal of Clinical Endocrinology & Metabolism, September 1995, Endocrine Society

    Dr Bruno P Imbimbo

  186. The effect of hexarelin on growth hormone (GH) secretion in patients with GH deficiency

    Article • The Journal of Clinical Endocrinology & Metabolism, September 1995, Endocrine Society

    Dr Bruno P Imbimbo

  187. Comparison of the effects of growth hormone-releasing hormone and hexarelin, a novel growth hormone-releasing peptide-6 analog, on growth hormone secretion in humans with or without glucocorticoid excess

    Article • Journal of Endocrinology, August 1995, Bioscientifica

    Dr Bruno P Imbimbo

  188. A Patient-Side Technique for Real-Time Measurement of Acetylcholinesterase Activity During Monitoring of Eptastigmine Treatment

    Article • Therapeutic Drug Monitoring, June 1995, Wolters Kluwer Health

    Dr Bruno P Imbimbo

  189. Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, before and during puberty.

    Article • The Journal of Clinical Endocrinology & Metabolism, April 1995, Endocrine Society

    Dr Bruno P Imbimbo

  190. Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, before and during puberty

    Article • The Journal of Clinical Endocrinology & Metabolism, April 1995, Endocrine Society

    Dr Bruno P Imbimbo

  191. Relationship Between Pharmacokinetics and Pharmacodynamics of Eptastigmine in Young Healthy Volunteers

    Article • The Journal of Clinical Pharmacology, March 1995, Wiley

    Dr Bruno P Imbimbo

  192. The growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, in short normal and obese children and in hypopituitary subjects.

    Article • The Journal of Clinical Endocrinology & Metabolism, February 1995, Endocrine Society

    Dr Bruno P Imbimbo

  193. The growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, in short normal and obese children and in hypopituitary subjects

    Article • The Journal of Clinical Endocrinology & Metabolism, February 1995, Endocrine Society

    Dr Bruno P Imbimbo

  194. Hexarelin, a novel GHRP-6 analog, counteracts the inhibitory effect of hydrocortisone on growth hormone secretion in acromegaly

    Article • Endocrine Research, January 1995, Taylor & Francis

    Dr Bruno P Imbimbo

  195. Hexarelin, a potent GHRP analogue: Interactions with GHRH and clonidine in young and aged dogs

    Article • Peptides, January 1995, Elsevier

    Dr Bruno P Imbimbo

  196. Mechanism of Action of Hexarelin and GHRP-6: Analysis of the Involvement of GHRH and Somatostatin in the Rat

    Article • Neuroendocrinology, January 1995, Karger Publishers

    Dr Bruno P Imbimbo

  197. Metabolic modulation of the growth hormone-releasing activity of hexarelin in man

    Article • Metabolism, January 1995, Elsevier

    Dr Bruno P Imbimbo

  198. Modulation of Growth Hormone-Releasing Activity of Hexarelin in Man

    Article • Neuroendocrinology, January 1995, Karger Publishers

    Dr Bruno P Imbimbo

  199. Arginine and growth hormone-releasing hormone restore the blunted growth hormone-releasing activity of hexarelin in elderly subjects

    Article • The Journal of Clinical Endocrinology & Metabolism, November 1994, Endocrine Society

    Dr Bruno P Imbimbo

  200. Distension-stimulated propagated contractions in human colon

    Article • Digestive Diseases and Sciences, September 1994, Springer Science + Business Media

    Dr Bruno P Imbimbo

  201. Growth hormone-releasing activity of hexarelin in humans

    Article • European Journal of Clinical Pharmacology, June 1994, Springer Science + Business Media

    Dr Bruno P Imbimbo

  202. Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, after intravenous, subcutaneous, intranasal, and oral administration in man.

    Article • The Journal of Clinical Endocrinology & Metabolism, March 1994, Endocrine Society

    Dr Bruno P Imbimbo

  203. Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, after intravenous, subcutaneous, intranasal, and oral administration in man

    Article • The Journal of Clinical Endocrinology & Metabolism, March 1994, Endocrine Society

    Dr Bruno P Imbimbo

  204. A Pharmacodynamic Strategy to Optimize the Clinical Response to Eptastigmine (MF-201)

    Article • January 1994, Springer Science + Business Media

    Dr Bruno P Imbimbo

  205. Biliary excretion of rufloxacin in humans.

    Article • Antimicrobial Agents and Chemotherapy, December 1993, ASM Journals

    Dr Bruno P Imbimbo

  206. Pharmacodynamics and pharmacokinetics of eptastigmine in elderly subjects

    Article • European Journal of Clinical Pharmacology, November 1993, Springer Science + Business Media

    Dr Bruno P Imbimbo

  207. Effects of magnesium-aluminum hydroxide antacid on absorption of rufloxacin.

    Article • Antimicrobial Agents and Chemotherapy, October 1993, ASM Journals

    Dr Bruno P Imbimbo

  208. Multiple-dose pharmacokinetics of rufloxacin in patients with cirrhosis

    Article • Hepatology, October 1993, Wiley

    Dr Bruno P Imbimbo

  209. Prolonged Effects of Cholinesterase Inhibition with Eptastigmine on the Cerebral Blood Flow-Metabolism Ratio of Normal Rats

    Article • Journal of Cerebral Blood Flow & Metabolism, July 1993, SAGE Publications

    Dr Bruno P Imbimbo

  210. Impaired colonic motor response to cholinergic stimulation in patients with severe chronic idiopathic (slow transit type) constipation

    Article • Digestive Diseases and Sciences, June 1993, Springer Science + Business Media

    Dr Bruno P Imbimbo

  211. Rapid potentiometric determination of cholinesterases in plasma and red cells: Application to eptastigmine monitoring

    Article • Chemico-Biological Interactions, June 1993, Elsevier

    Dr Bruno P Imbimbo

  212. Pharmacokinetics of rufloxacin in patients with impaired renal function.

    Article • Antimicrobial Agents and Chemotherapy, April 1993, ASM Journals

    Dr Bruno P Imbimbo

  213. The pharmacokinetics and pharmacodynamics of dermatan sulphate MF701 during haemodialysis for chronic renal failure.

    Article • British Journal of Clinical Pharmacology, March 1993, Wiley

    Dr Bruno P Imbimbo

  214. Pharmacokinetics of intramuscular dermatan sulfate (MF701) in patients with hip fracture

    Article • Thrombosis Research, January 1993, Elsevier

    Dr Bruno P Imbimbo

  215. Comparison of two glucocorticoid preparations (deflazacort and prednisone) in the treatment of immune-mediated diseases

    Article • European Journal of Clinical Pharmacology, January 1993, Springer Science + Business Media

    Dr Bruno P Imbimbo

  216. Eptastigmine augments basal and GHRH-stimulated growth hormone release in young and old dogs

    Article • Life Sciences, January 1993, Elsevier

    Dr Bruno P Imbimbo

  217. The penetration of rufloxacin into sites of potential infection in the respiratory tract

    Article • Journal of Antimicrobial Chemotherapy, January 1993, Oxford University Press (OUP)

    Dr Bruno P Imbimbo

  218. Multiple-dose pharmacokinetics and safety of rufloxacin in normal volunteers.

    Article • Antimicrobial Agents and Chemotherapy, June 1992, ASM Journals

    Dr Bruno P Imbimbo

  219. Pharmacokinetics of rufloxacin once daily in patients with lower respiratory tract infections

    Article • Infection, March 1992, Springer Science + Business Media

    Dr Bruno P Imbimbo

  220. Gallbladder hypokinesia and normal gastric emptying of liquids in patients with dyspeptic symptoms

    Article • Digestive Diseases and Sciences, February 1992, Springer Science + Business Media

    Dr Bruno P Imbimbo

  221. Steady-State Pharmacokinetics of Rufloxacin in Elderly Patients with Lower Respiratory Tract Infections

    Article • Therapeutic Drug Monitoring, February 1992, Wolters Kluwer Health

    Dr Bruno P Imbimbo

  222. 059 Preliminary data on heptastigmine monitoring

    Article • Fresenius Journal of Analytical Chemistry, January 1992, Springer Science + Business Media

    Dr Bruno P Imbimbo

  223. High performance liquid chromatography and preliminary pharmacokinetics of rufloxacin and its metabolites N-desmethylrufloxacin and rufloxacinsulfoxide in plasma and urine of humans

    Article • European Journal of Drug Metabolism and Pharmacokinetics, January 1992, Springer Science + Business Media

    Dr Bruno P Imbimbo

  224. High-performance liquid chromatography and preliminary pharmacokinetics of rufloxacin and its metabolites, N-desmethylrufloxacin and rufloxacinsulfoxide, in urine of Rhesus monkey Macaca mulatta

    Article • Journal of Chromatography B Biomedical Sciences and Applications, January 1992, Elsevier

    Dr Bruno P Imbimbo

  225. Pharmacodynamics and pharmacokinetics of eptastigmine in elderly subjects

    Article • Neurobiology of Aging, January 1992, Elsevier

    Dr Bruno P Imbimbo

  226. Kinetics of cholinesterase inhibition by eptastigmine in man

    Article • European Journal of Clinical Pharmacology, July 1991, Springer Science + Business Media

    Dr Bruno P Imbimbo

  227. Edrophonium chloride for testing colonic contractile activity in man

    Article • Acta Physiologica Scandinavica, March 1991, Wiley

    Dr Bruno P Imbimbo

  228. Efficiency of different criteria for selecting pharmacokinetic multiexponential equations

    Article • Biopharmaceutics & Drug Disposition, March 1991, Wiley

    Dr Bruno P Imbimbo

  229. Inter- and intrasubject variabilities in the pharmacokinetics of rufloxacin after single oral administration to healthy volunteers.

    Article • Antimicrobial Agents and Chemotherapy, February 1991, ASM Journals

    Dr Bruno P Imbimbo

  230. Pharmacokinetics and tissue penetration of rufloxacin, a long acting quinolone antimicrobial agent

    Article • Journal of Antimicrobial Chemotherapy, January 1991, Oxford University Press (OUP)

    Dr Bruno P Imbimbo

  231. Pharmacokinetics of Rufloxacin in Healthy Volunteers after Repeated Oral Doses

    Article • Chemotherapy, January 1991, Karger Publishers

    Dr Bruno P Imbimbo

  232. Effects of cimetropium bromide on gallbladder contraction in response to oral and intraduodenal olive oil

    Article • European Journal of Clinical Pharmacology, October 1990, Springer Science + Business Media

    Dr Bruno P Imbimbo

  233. Inhibition of acetylcholinestense and butyrylcholinesterase after oral administration of heptastigmine in healthy volunteers

    Article • European Journal of Pharmacology, July 1990, Elsevier

    Dr Bruno P Imbimbo

  234. Longterm treatment of irritable bowel syndrome with cimetropium bromide: a double blind placebo controlled clinical trial.

    Article • Gut, March 1990, BMJ

    Dr Bruno P Imbimbo

  235. Comparative Study of the Effects of Cimetropium Bromide and Atropine on Human Esophageal Motor Functions

    Article • Digestion, January 1989, Karger Publishers

    Dr Bruno P Imbimbo

  236. Inhibition of caerulein-induced gall bladder emptying by cimetropium bromide in humans

    Article • European Journal of Clinical Pharmacology, January 1989, Springer Science + Business Media

    Dr Bruno P Imbimbo

  237. Efficacy of cimetropium bromide as pre-medication for double-contrast barium enema

    Article • British Journal of Radiology, November 1988, British Institute of Radiology

    Dr Bruno P Imbimbo

  238. Pharmacokinetics of mifentidine after single and multiple oral administration to healthy volunteers.

    Article • British Journal of Clinical Pharmacology, October 1988, Wiley

    Dr Bruno P Imbimbo

  239. A New Criterion for Selection of Pharmacokinetic Multiexponential Equations

    Article • Journal of Pharmaceutical Sciences, September 1988, Elsevier

    Dr Bruno P Imbimbo

  240. Colonic mass movements in idiopathic chronic constipation.

    Article • Gut, September 1988, BMJ

    Dr Bruno P Imbimbo

  241. Effect of mifentidine on peptone meal-stimulated gastric acid secretion and plasma gastrin levels in duodenal ulcer patients

    Article • Agents and Actions, August 1988, Springer Science + Business Media

    Dr Bruno P Imbimbo

  242. Gastric Acid and Pepsin Secretion after Single Oral Doses of Mifentidine in Healthy Subjects

    Article • Scandinavian Journal of Gastroenterology, January 1988, Taylor & Francis

    Dr Bruno P Imbimbo

  243. Manometric Evaluation of Cimetropium Bromide Activity in Patients with the Nutcracker Oesophagus

    Article • Scandinavian Journal of Gastroenterology, January 1988, Taylor & Francis

    Dr Bruno P Imbimbo

  244. Reduction by cimetropium bromide of the colonic motor response to eating in patients with the irritable bowel syndrome

    Article • European Journal of Clinical Pharmacology, January 1988, Springer Science + Business Media

    Dr Bruno P Imbimbo

  245. Safety and pharmacokinetics of mifentidine after increasing oral doses in healthy subjects

    Article • European Journal of Clinical Pharmacology, January 1988, Springer Science + Business Media

    Dr Bruno P Imbimbo

  246. Action of mifentidine on the secretory response to sham feeding and pentagastrin and on serum gastrin in duodenal ulcer patients

    Article • European Journal of Clinical Pharmacology, August 1987, Springer Science + Business Media

    Dr Bruno P Imbimbo

  247. Transverse and Sigmoid Colon Motility in Healthy Humans: Effects of Eating and of Cimetropium Bromide

    Article • Digestion, January 1987, Karger Publishers

    Dr Bruno P Imbimbo

  248. Urinary excretion of cimetropium bromide after multiple oral doses

    Article • European Journal of Clinical Pharmacology, January 1987, Springer Science + Business Media

    Dr Bruno P Imbimbo

  249. Discontinuous Oral Absorption of Cimetropium Bromide, a New Antispasmodic Drug

    Article • Journal of Pharmaceutical Sciences, July 1986, Elsevier

    Dr Bruno P Imbimbo

  250. Cimetropium bromide as a relaxant for the radiological examination of the stomach and duodenum

    Article • Current Medical Research and Opinion, January 1986, Informa Healthcare

    Dr Bruno P Imbimbo

  251. Effects of Pirenzepine and Atropine on Gastroduodenal Motor Patterns in Duodenal Ulcer Patients

    Article • Scandinavian Journal of Gastroenterology, January 1986, Taylor & Francis

    Dr Bruno P Imbimbo

  252. The Use of Cimetropii Bromidum as Premedication for Endoscopy of the Upper Gastro-Intestinal Tract: A Double-Blind Controlled Clinical Trial

    Article • Journal of International Medical Research, November 1985, SAGE Publications

    Dr Bruno P Imbimbo